http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-035230-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate | 2002-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-035230-A1 |
| titleOfInvention | BENCIMIDAZOL COMPOUNDS, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION, AND USES OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES |
| abstract | A compound having the general formula (1) in which A represents an oxygen atom or an NH group; each X independently represents a nitrogen atom or a CH group; m is 0, 1, 2, 3, or 4; Each R1 independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1- haloalkyl 6, C1-6 haloalkoxy, -NR9R10, C3-6 cycloalkylamino, C1-6 alkylthio, C1-6 alkylcarbonyl, C1-6 alkylcarbonylamino, sulfonamido, C1-6 alkylsulfonyl or -C (O) NR11R12; n represents 0, 1 or 2; each R2 independently represents a C1-6 alkyl, C1-6 alkoxycarbonyl, -CH2OH or carboxyl group; Z1 represents a bond or a group (CH2) q where q is 1 or 2; Z2 represents a link or a CH2 group, with the proviso that Z1 and Z2 do not simultaneously represent a link; Q represents an oxygen or sulfur atom or a CH2 or NH group; R3 represents -NHC (O) R13, -C (O) NR14R15, -NH-R15a or O-R15b, or R3 together with the six-member ring to which it is attached forms a group of the formula 2 or 3; each of R4, R5, R6 and R7 independently represent a hydrogen atoms or a C1-6 alkyl group or R4, R5, R6 and R7 together, represent a C1-4 alkylene chain linking the two carbon atoms to which are joined to form a saturated carbocycle of 4 to 7 members, or each of R5, R6 and R7 represents a hydrogen atoms and R4 and R8 together with the carbon atoms to which they are attached form a saturated carbocycle of 5 to 6 members; R8 represents a hydrogen atom, a C1-6 alkyl group or is linked to R4 as defined above; Each of R9 and R10 represents a hydrogen atom or a C1-6 alkyl group or R9 and R10 together with the nitrogen atom to which a saturated 4- to 7-membered heterocycle is attached; each of R11 and R12 independently represents a hydrogen atom or a C1-6 alkyl group, R13 represents a C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, adamantyl, C5-6 cycloalkenyl, phenyl or a system group 5 to 10 membered heterocyclic ring, saturated or unsaturated, comprising at least one heteroatom in the ring selected from the group consisting of nitrogen, oxygen and sulfur, each of which may be optionally substituted with one or more independently selected substituents among nitro, hydroxy, oxo, halogen, carboxyl, C1-6 alkyl, C1-6 alkoxy C1-6 alkylthio, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, phenyl and -NHC (O) -R17; each of R14 and R15 independently represents (i) a hydrogen atoms (ii), a saturated or unsaturated ring of 3 to 6 members that optionally comprises at least one ring heteroatom selected from nitrogen, oxygen, sulfur, where the ring is optionally substituted with at least one substituent selected from hydroxyl, halogen, methyl, methoxy and trifluoromethyl, or (iii) a C1-6 alkyl group optionally substituted with at least one substituent selected from halogen, trifluoromethyl, carboxyl, C1- alkoxycarbonyl 6 and a saturated or unsaturated 5 to 6 membered ring that optionally comprises at least one ring heteroatom selected from nitrogen, oxygen and sulfur, where the ring is optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or R14 and R15 together with the nitrogen atom to which they are attached form a saturated 4- to 7-membered heterocycle; each of R15a and R15b independently represents a saturated 5- or 6-membered saturated or unsaturated heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulfur, where the ring is optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl; t is 0, 1, 2 or 3; each R16 independently represents halogen, cyano, nitro, carboxyl, hydroxy, cycloalkyl, C3-6, C1-6 alkoxy, CC1-6 alkoxycarbonyl, C1-6 haloalkyl, C1-6 haloalkoxy, -NR18R19, C3-6 cycloalkylamino, C1 alkylthio -6, C1-6 alkylcarbonyl, C1-6 alkylcarbonylamino, sulfonamido, C1-6 alkylsulfonyl, -C (O) NR20R21, -NR22C (O) (NH) vR23, phenyl, or C1-6 alkyl optionally substituted with at least a substituent selected from carboxyl and C1-6 alkoxycarbonyl; R17 represents a C1-6 alkyl, amino or phenyl group; each of R18 and R19 independently represents a hydrogen atom or a C1-6 alkyl group, or R18 and R19 together with the nitrogen atom to which they are attached form a saturated 4- to 7-membered heterocycle; each of R20 and R21 independently represents a hydrogen atom or a C1-6 alkyl group optionally substituted with C1-6 alkoxycarbonyl, v is 0 or 1; R22 represents a hydrogen atom or a C1-6 alkyl group; and R23 represents a hydrogen atom or a C1-6 alkyl group optionally substituted with at least one substituents selected from carboxyl, C1-6 alkoxy and C1-6 alkoxycarbonyl, or a pharmaceutically acceptable salt or solvate thereof; process for its preparation, pharmaceutical composition, process for the preparation of said pharmaceutical composition and uses of these compounds for the preparation of medicaments. |
| priorityDate | 2001-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.